TELO shareholders approve acquisition of Teli Pharma and increase share reserve to 11.5M

Telomir Pharmaceuticals, Inc.

Acquisition of Teli Pharmaceuticals approved; issuance of >20% new shares authorized.
2023 Omnibus Incentive Plan amended: share reserve increased from 6.5M to 11.5M shares and repricing allowed.
Bylaws amended to reduce quorum requirement to one-third of outstanding shares.
Directors elected: Erez Aminov, Matthew Whalen, Edward MacPherson, Matthew Del Giudice.
Ratification of Salberg & Company as independent auditor for FY 2025 approved.

item 5.02item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.